BenevolentAI Investor Conference Presentation Deck

Strategic collaboration with Merck KGaA Leverages End-to-End Drug Discovery capabilities including our wet lab facility in Cambridge (UK) Identify and develop innovative small molecule compounds, through Hit Identification to preclinical stage Initial delivery of three novel small molecule drug candidates THERAPEUTIC AREAS Oncology FINANCIAL TERMS ()) MERCK ● End-to-End Drug Discovery Neurology BenevolentAl Proprietary September 2023 Up to $594 million of total value, including: • Low double-digit million dollar upfront Immunology Tiered royalties on net sales of any commercialised products payment Discovery, development and commercial milestones Benevolent 6

View entire presentation